123I-MIBG显像与全身弥散加权MRI在儿童高危神经母细胞瘤中的评分比较:初步研究
该回顾性观察研究纳入2010至2015年间17例高危4期神经母细胞瘤患儿共25对检查,比较SIOPEN骨骼评分在123I-MIBG显像与全身弥散加权MRI上的差异。MIBG评分中位0分 vs 全身MRI中位1分(P=0.018),14/25对检查存在临床相关差异(MRI更高9例、MIBG更高5例)。作者认为SIOPEN评分系统可用于全身MRI,但MRI可能因空间分辨率更高而得到略高的评分,对预后的影响需进一步研究验证。
要点
- SIOPEN骨骼评分系统可尝试用于全身弥散加权MRI,但MRI评分可能略高于MIBG。
- 25对检查中14对存在临床相关差异,其中MRI评分更高9对、MIBG更高5对。
- MRI评分更高者与MIBG更高者的生存差异无统计学意义(P=0.413)。
局限性
- 原文为初步研究,样本量小(17例患儿、25对检查)。
- 原文为回顾性观察研究。
- 对预后影响的验证需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND: The prognostic value of the International Society of Paediatric Oncology European Neuroblastoma Research Network (SIOPEN) skeletal score using 123iodine-metaiodobenzylguanidine (MIBG) has been confirmed for people with high-risk neuroblastoma. Whole-body MRI with diffusion-weighted imaging is used increasingly.
OBJECTIVE: To compare the original SIOPEN score and its adaption by diffusion-weighted imaging in high-risk stage 4 neuroblastoma and to evaluate any consequences of score differences on overall survival.
MATERIALS AND METHODS: This retrospective observational study included pediatric patients who underwent MIBG scintigraphy and whole-body MRI, including diffusion-weighted imaging, between 2010 and 2015. Semi-quantitative skeletal scores for each exam were calculated independently. A difference of two or more points was defined as clinically relevant and counted as M+ (more in diffusion-weighted imaging) or S+ (more in MIBG). In cases of a negative result in one of the studies, residual disease of 1 point was also rated as relevant. We tested correlation and differences on an exam basis and also grouped by different therapeutic conditions. Overall survival was used to evaluate prognostic relevance.
RESULTS: Seventeen children with 25 paired examinations were evaluated. Median MIBG scintigraphy score was 0 (interquartile range [IQR] 0-4, range 0-25) vs. a median whole-body MRI score of 1 (IQR 0-5.5, range 0-35) (P=0.018). A relevant difference between whole-body MRI and MIBG scintigraphy was noted in 14 of the 25 paired examinations (M+: n=9; S+: n=5). After treatment, the median survival of cases with M+ was 14 months (IQR 4-59, range 1-74 months), while S+ cases showed a median survival of 49 months (IQR 36-52, range 36-52 months) (P=0.413).
CONCLUSION: The SIOPEN scoring system is feasible for whole-body MRI but might result in slightly higher scores, probably because of MRI's superior spatial resolution. Further studies are necessary to validate any impact on prognosis.
引用
- Gassenmaier S, Bares R, Barreuther M, et al. 123Iodine-metaiodobenzylguanidine scintigraphy versus whole-body magnetic resonance imaging with diffusion-weighted imaging in children with high-risk neuroblastoma - pilot study. Pediatr Radiol. 2021. PMID: 33544193. doi:10.1007/s00247-020-04960-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。